

## Arcus Biosciences Announces Participation at Upcoming Investor Conference

5/29/2018

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 8:40 am PT at the Terranea Resort, in Rancho Palos Verdes, CA.

Individuals may access the live audio webcast by visiting the “Events & Presentations” section of the Company’s website at <https://investors.arcusbio.com/investors/investor-relations/default.aspx>. A replay of the webcast will be available for 30 days following the live event.

### About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. For more information about Arcus Biosciences, please visit [www.arcusbio.com](http://www.arcusbio.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20180529006103/en/>

Arcus Biosciences, Inc.  
Jennifer Jarrett, 510-694-6261

**jjarrett@arcusbio.com**

or

Nicole Arndt, 510-284-4728

**narndt@arcusbio.com**

Source: Arcus Biosciences, Inc.